Moderna
MRNA
548 hedge funds and large institutions have $14.5B invested in Moderna in 2020 Q3 according to their latest regulatory filings, with 140 funds opening new positions, 222 increasing their positions, 138 reducing their positions, and 79 closing their positions.
77% more first-time investments, than exits
New positions opened: 140 | Existing positions closed: 79
61% more repeat investments, than reductions
Existing positions increased: 222 | Existing positions reduced: 138
12% more funds holding
Funds holding: 490 → 548 (+58)
3% more capital invested
Capital invested by funds: $14.1B → $14.5B (+$421M)
0% more funds holding in top 10
Funds holding in top 10: 10 → 10 (0)
4.42% less ownership
Funds ownership: 56.39% → 51.97% (-4.4%)
21% less call options, than puts
Call options by funds: $672M | Put options by funds: $848M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$221M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$157M |
| 3 |
JP Morgan Chase
New York
|
+$39.7M |
| 4 |
State Street
Boston,
Massachusetts
|
+$38.8M |
| 5 |
Legal & General Group
London,
United Kingdom
|
+$36.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
-$628M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$231M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$183M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$125M |
| 5 |
Morgan Stanley
New York
|
-$94.2M |
MRNA Hedge Fund Activity: Q3 2020 in Review
548 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Moderna (MRNA) for Q3 2020, worth a combined $14.5B — up 3% from $14.1B a quarter earlier.
Buyers outnumbered sellers: 140 funds opened new MRNA positions and 79 closed out — a net gain of 61 holders — while 222 added to existing stakes and 138 trimmed.
The largest buyer was Baillie Gifford & Co, adding an estimated $221M. The largest seller was Flagship Pioneering, cutting an estimated $628M.
- 548 institutional investors held Moderna (MRNA) as of Q3 2020, up from 490 in Q2 2020.
- Funds reported $14.5B of Moderna stock for Q3 2020, up 3% quarter-over-quarter.
- 140 funds opened new Moderna positions in Q3 2020 and 79 closed out, a net change of +61 holders.
- The largest Moderna buyer in Q3 2020 was Baillie Gifford & Co, an estimated $221M added.
- The largest Moderna seller in Q3 2020 was Flagship Pioneering, an estimated $628M sold.
Based on aggregated 13F filings for Q3 2020.